Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 14/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18673304 | 0.96 | PTGFR (0.44) | PTGFRABCC4ABCB11PTGER3CNR1 | |
| SCHEMBL17686186 | 0.79 | PTGFR (0.68) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL17686189 | 0.79 | PTGFR (0.68) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL17686184 | 0.79 | PTGFR (0.68) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL17696812 | 0.78 | CNR1 (0.49) | PTGFRABCC4ABCB11PTGER3CNR1 | |
| SCHEMBL17696713 | 0.74 | PTGFR (0.69) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL18673303 | 0.72 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL12119609 | 0.69 | PTGFR (0.73) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL12119720 | 0.69 | PTGFR (0.73) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL13008203 | 0.69 | PTGFR (0.81) | PTGFRABCC4ABCB11PTGER3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604949-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | PTGFR 5/4885ABCC4 1489/4885ABCB11 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.